Navigation Links
Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
Date:11/18/2013

BASKING RIDGE, N.J., Nov. 18, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of Pierre Legault, MBA, CA, CPA, to its Board of Directors, where he will serve as Chairman of the audit committee. 

Mr. Legault has extraordinarily broad executive management experience, including more than 30 years spent executing creative financing strategies, driving corporate development, and constructing value-driving transactions for international biotechnology and pharmaceutical companies.  In addition, Mr. Legault has significant experience serving on the board of directors and audit committees of public companies.

Mr. Legault is currently CEO of NephroGenex, a late-stage biotech company, and was previously Executive Chairman.  He is also President and CEO of Stone Management LLC, a firm focused in the areas of business development and board assistance.  From 2009 to 2012, he held leadership positions at Astellas Pharmaceuticals and its legacy companies, including Chief Executive Officer of Prosidion Ltd., and Executive VP, CFO and Treasurer of OSI Pharmaceuticals.  From January 2006 to December 2008, Mr. Legault worked for Rite Aid Corporation, a Fortune 500 publicly traded pharmaceutical retail company, most recently as senior executive vice president and chief administrative officer.  Prior to Rite Aid Corporation, Mr. Legault held several senior positions over 15+ years at Sanofi-Aventis and predecessor companies, serving most recently as Worldwide President of a large, global dermatology business unit.

In addition, Mr. Legault has served on several public, private and nonprofit company boards and audit committees, including Forest Laboratories, Inc., on which he serves currently as audit committee Chairman.  Prior board positions include OSI Investment Holdings GMBH (Chairman), Cyclacel Pharmaceutical Inc., PJC Inc., as well as other private boards.  Mr. Legault studied at the Harvard Business School in an executive masters program and he received his MBA from McGill University and his BAA from University of Montreal (HEC).  He also holds CA and CPA degrees.

Mr. Legault stated, "Throughout my career I have chosen board appointments very carefully, and I see a tremendous opportunity in Regado.  As the company continues to drive toward clinical success with REG1, I look forward to offering my expertise and guidance."

Dennis Podlesak, MBA, Regado's Board Chairman, stated, "We are very pleased to add Mr. Legault to our board of directors and as our audit committee Chairman.  We believe his specific expertise in this role will be a valuable asset for Regado, as will his impressive background in running international pharmaceutical companies across the full spectrum of clinical and commercial development." 

ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications.  Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen.  REG1 is being developed for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at www.regadobio.com.

For more information on REGULATE-PCI, please visit: 
http://www.clinicaltrials.gov/ct2/show/NCT01848106?term=Regado&rank=1

Contact: 
Tiberend Strategic Advisors, Inc.

Investors - Joshua Drumm, Ph.D. 
jdrumm@tiberend.com; (212) 375-2664

Media - Andrew Mielach 
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
2. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
3. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
8. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
9. Jeeven BioSciences, Inc. Announces the Release of its Neuro-X(TM) Serum Free and Xeno Free Tissue Culture Media
10. SeeThruEquity, LLC Initiates Coverage on Pressure BioSciences, Inc.
11. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global Wound ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 and ... Among the various wound care products type, the advanced wound ... 2015. Among the various applications, surgical wound segment held the largest share ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary ... Medical cannabis products around ... Research, Inc., projects that the global medical cannabis market will reach a ... is a major market for the new growing industry. By the ... to legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology:
(Date:3/27/2017)... Fla. (PRWEB) , ... March 27, 2017 , ... ... overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the ... McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription ...
(Date:3/25/2017)... ... ... Norland at Swissray is pleased to announce the release of the ELITE DXA, ... has an active scan window, which is more than double that of existing bone densitometers. ... could not undergo an accurate total body bone density or body composition study. ...
(Date:3/24/2017)... Greenville, SC (PRWEB) , ... March 24, 2017 , ... ... , is excited to announce the opening of a Greenville, South Carolina ... center for digital progress in Greenville. , “We’ve been working with South Carolina clients ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
Breaking Medicine News(10 mins):